NCT05156866: First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer

NCT05156866
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with progressive or symptomatic brain metastases
https://ClinicalTrials.gov/show/NCT05156866

Comments are closed.

Up ↑